CoNCERT Pharmaceuticals Inc.

Lexington, MA
website

CoNCERT is creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. It applies its innovative platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities. CoNCERT leverages decades of pharmaceutical experience to create drug candidates with potential for best-in-class efficacy and safety, while greatly reducing R&D risk, time and expense. The Company has over 100 patent applications for new drug candidates addressing a broad range of therapeutic areas, including hot flashes, fibrotic diseases, pain and infectious disease.

Co-investors include Adage Capital Management L.P., SR One Ltd., Westfield Capital Management, Three Arch Partners, TVM Capital, Skyline Ventures, Brookside Capital Partners Fund, LP, Flagship Ventures, Greylock Partners, New Leaf Venture Partners, and QVT Fund LP.
 

 

DiscoveRx, Inc.

Fremont, CA
website

DiscoveRx develops a portfolio of high performance biochemical reagents for use in a broad range of drug discovery assays. These assays include drug lead identification in high throughput screening as well as drug target identification and validation in proteomic and genomic studies.

Co-investors in the company include Skyline Ventures, Morgan Stanley Ventures and Alta Partners.
 

 

ImpactRx, Inc.

Mt. Laurel, NJ
website

 

ImpactRx was founded by Mediphase. ImpactRx is a promotion research company providing detailed analysis of the effects of pharmaceutical company promotional efforts. ImpactRx builds exclusive networks of high-prescribing physicians who provide real-time diagnosis, drug and promotion information. Products include PromoLink, SalesForceLink and SalesFX, and are used to direct promotional activities and sales force deployment.

Co-investors include Oxford Bioscience Partners, Merck Capital Ventures and 3i. Larry Miller is a member of the Board.
 

 

PatientKeeper, Inc.

Newton, MA
website

 

PatientKeeper develops software for hand-held devices (PDAs) for physicians and allied health personnel. Applications include charge capture, clinical results, prescriptions and dictation. The company also provides a sophisticated back-end database and synchronizing capability. PatientKeeper’s customers comprise more than 300 hospitals, including major teaching hospitals and community hospital systems.

Co-investors include NEA, Frazier and Co. and J.H. Whitney and Co. Larry Miller is a member of the Board.
 

 

Relypsa, Inc.

Santa Clara, CA
website

 

Relypsa, Inc. is a biopharmaceutical company leading the discovery and development of new non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. The new company is a spin-out of Ilypsa, Inc., a wholly-owned subsidiary of Amgen, Inc. (acquired by Amgen in July 2007 for $ 420 M). Relypsa commenced operations with rights to a proprietary drug discovery platform and a pipeline of product candidates, including a potassium binder drug candidate for the treatment of hyperkalemia, known as RLY5016, as well as a novel sodium binder, RLY102, for the potential treatment of congestive heart failure. RLY 5016 is currently in phase II trials. Relypsa is dedicated to discovering additional product candidates through use of its proprietary polymer platform.

Co-investors include, 5AM Ventures, New Leaf and Delphi.
 

 

Roxro Pharma, Inc.

Menlo Park, CA
website

 

Roxro Pharma’s first product, ROX-888, is a reformulation of ketorolac (an approved analgesic) for the management of postoperative pain. Because it can be delivered intranasally, and delivery can therefore be controlled by the patient, the drug is a good candidate for outpatient or ambulatory settings. Roxro is currently completing its final manufacturing data as it prepares for an NDA submission later this year.

Co-investors include Sutter Hill Ventures and Prospect Ventures.
 

 

STARTech, Inc.

Richardson, TX
website

 

STARTech is a Dallas-based "accelerator" providing early stage companies with a broad range of financial, legal and administrative assistance, including the services of experienced "mentors" who can provide direct tactical and strategic advice. The company focuses on information technology approaches to health care and other sectors.

Co-investors include Sevin Rosen, InterWest Partners, Rho Management and CenterPoint Ventures.
 

 

Supplemental Health Care

Park City, UT
website

 

Supplemental provides staffing services to hospitals and other health care facilities, including traveling and local staffing of nurses and ancillary hospital personnel, such as radiology technicians, physical therapists, and occupational therapists. Supplemental is one of the top ten nurse and therapist staffing companies in the U.S.

Co-investors include GE Capital and Dauphin Capital Partners. Paul Howard is a member of the board.
 

 

Tetraphase Pharmaceuticals, Inc.

Watertown, MA
website
 

 

Tetraphase Pharmaceuticals was founded by Mediphase. Tetraphase develops antibiotics in the tetracycline class, based on synthetic technology developed by Prof. Andrew Myers and licensed from Harvard University.

Co-investors include Fidelity Biosciences, Skyline Ventures, Flagship Ventures and CMEA Ventures. Larry Miller is Board Chairman.
 

 

Wellpartner

Portland, OR
website

 

Wellpartner is a pharmacy benefit manager (PBM) focusing on mail order drug delivery, primarily in Medicaid plans. The recent financing will support significant expansion of capacity and sales/marketing. We believe that the management has unusual expertise in the complex Medicaid arena, and the company is poised for rapid growth over the next 24 months.

Co-investors include 3i Technology Partners, Integra Ventures, and Buerk Dale Victor.
 

© Mediphase Venture Partners